Starpharma, a key player in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications has signed a collaborative research agreement with Stiefel Laboratories, an independent pharmaceutical company specializing in dermatology, to apply its dendrimer nanotechnology to certain drugs used dermally.

An Australia based Starpharma, a key player in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications has signed a collaborative research agreement with Stiefel Laboratories, an independent pharmaceutical company specializing in dermatology, to apply its dendrimer nanotechnology to certain drugs used dermally. Stiefel Laboratories has five global research and development centers and has products marketed in more than 100 countries around the world.

The collaboration will apply Starpharma’s dendrimer technology to deliver drugs through the skin with the aim of improving the effectiveness and tolerability of certain dermal treatments. Under the terms of the agreement Starpharma will receive staged payments on successful completion of technical milestones within the collaborative project. The agreement also deals with commercialization rights arising from the collaboration.

This is the fourth agreement signed by Starpharma this year to develop commercial applications for its dendrimer technology. Starpharma also has dendrimer drug delivery programs underway in cancer and protein therapeutics. In February 2007 Starpharma entered into a worldwide exclusive license and supply agreement with EMD Biosciences, part of Merck KGaA's Performance and Life Science Chemicals division.